CNBX Pharmaceuticals Inc
OTC:CNBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CNBX Pharmaceuticals Inc
Revenue
CNBX Pharmaceuticals Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CNBX Pharmaceuticals Inc
OTC:CNBX
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$96.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$65B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$65.2B
|
CAGR 3-Years
32%
|
CAGR 5-Years
22%
|
CAGR 10-Years
13%
|
|
CNBX Pharmaceuticals Inc
Glance View
Cannabics Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Bethesda, Maryland and currently employs 10 full-time employees. The company went IPO on 2007-07-02. The firm specializes in the discovery, development and commercialization of cannabinoid-based products and technologies for the treatment of cancer. The company focuses on development and marketing of bioinformatic delivery systems for cannabinoids, personalized medicine therapies and procedures based on cannabis originated compounds and bioinformatics tools. Its bioinformatics platform utilizes screening technology, advanced data analytics, and methodologies to examine the physiologic effect of multiple cannabinoid compounds on tumor cells. The firm's product pipeline includes RCC-33, Cannabics SR, and Cannabics CDx. Its lead product candidate is RCC-33, an oral capsule for the treatment of colorectal cancer (CRC). RCC-33 contains high concentrations of the cannabinoids Cannabidivarin (CBDV), and Cannabigerolic acid (CBGA).
See Also
What is CNBX Pharmaceuticals Inc's Revenue?
Revenue
0
USD
Based on the financial report for Nov 30, 2025, CNBX Pharmaceuticals Inc's Revenue amounts to 0 USD.
